Agios Pharmaceuticals Inc (AGIO)
29.59
+0.16
(+0.54%)
USD |
NASDAQ |
Apr 19, 13:10
Agios Pharmaceuticals Revenue (Quarterly): 7.103M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.103M |
| September 30, 2023 | 7.399M |
| June 30, 2023 | 6.712M |
| March 31, 2023 | 5.609M |
| December 31, 2022 | 4.31M |
| September 30, 2022 | 3.516M |
| June 30, 2022 | 5.582M |
| March 31, 2022 | 0.832M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -82.47M |
| September 30, 2019 | 26.02M |
| June 30, 2019 | 26.22M |
| March 31, 2019 | 30.23M |
| December 31, 2018 | 30.01M |
| September 30, 2018 | 15.20M |
| June 30, 2018 | 40.41M |
| March 31, 2018 | 8.762M |
| Date | Value |
|---|---|
| December 31, 2017 | 9.799M |
| September 30, 2017 | 11.36M |
| June 30, 2017 | 11.35M |
| March 31, 2017 | 10.51M |
| December 31, 2016 | 22.65M |
| September 30, 2016 | 8.985M |
| June 30, 2016 | 6.978M |
| March 31, 2016 | 31.28M |
| December 31, 2015 | 6.218M |
| September 30, 2015 | 5.48M |
| June 30, 2015 | 13.22M |
| March 31, 2015 | 34.20M |
| December 31, 2014 | 14.64M |
| September 30, 2014 | 33.90M |
| June 30, 2014 | 8.411M |
| March 31, 2014 | 8.411M |
| December 31, 2013 | 6.744M |
| September 30, 2013 | 6.268M |
| June 30, 2013 | 6.268M |
| March 31, 2013 | 6.268M |
| December 31, 2012 | 6.282M |
| September 30, 2012 | 6.268M |
| June 30, 2012 | 6.288M |
| March 31, 2012 | 6.268M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-82.47M
Minimum
Dec 2019
26.22M
Maximum
Jun 2019
0.9851M
Average
5.609M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 439.72M |
| Blueprint Medicines Corp | 71.96M |
| Corcept Therapeutics Inc | 135.40M |
| Ionis Pharmaceuticals Inc | 324.50M |
| Madrigal Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -95.94M |
| Total Expenses (Quarterly) | 113.38M |
| EPS Diluted (Quarterly) | -1.72 |
| Enterprise Value | 876.88M |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -1.35K% |
| Earnings Yield | -21.43% |
| Normalized Earnings Yield | -21.43 |